Avinger, Inc. (NASDAQ:AVGR) Short Interest Down 31.3% in August

Avinger, Inc. (NASDAQ:AVGR) saw a significant decline in short interest in August. As of August 15th, there was short interest totalling 68,100 shares, a decline of 31.3% from the July 31st total of 99,100 shares. Currently, 4.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 51,000 shares, the short-interest ratio is currently 1.3 days.

Institutional Investors Weigh In On Avinger

A hedge fund recently bought a new stake in Avinger stock. Armistice Capital LLC purchased a new stake in shares of Avinger, Inc. (NASDAQ:AVGR) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 43,747 shares of the medical device company’s stock, valued at approximately $81,000. Armistice Capital LLC owned approximately 2.57% of Avinger at the end of the most recent quarter. 18.30% of the stock is currently owned by institutional investors and hedge funds.

Avinger Price Performance

NASDAQ:AVGR remained flat at $1.10 during mid-day trading on Friday. 12,781 shares of the company were exchanged, compared to its average volume of 43,230. Avinger has a fifty-two week low of $1.00 and a fifty-two week high of $14.00. The stock has a market capitalization of $1.87 million, a PE ratio of -0.06 and a beta of 1.26. The business has a 50 day simple moving average of $1.50 and a 200-day simple moving average of $2.58.

Analysts Set New Price Targets

Separately, StockNews.com assumed coverage on Avinger in a research report on Friday. They set a “hold” rating on the stock.

About Avinger

Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.